Abstract:Background & aims: The American Consortium of Early Liver Transplantation for Alcoholic Hepatitis comprises 12 centers from 8 United Network for Organ Sharing regions studying early liver transplantation (LT) (without mandated period of sobriety) for patients with severe alcoholic hepatitis (AH). We analyzed the outcomes of these patients. Methods: We performed a retrospective study of consecutive patients with a diagnosis of severe AH and no prior diagnosis of liver disease or episodes of AH, who underwent LT before 6 months of abstinence from 2006 through 2017 at 12 centers. We collected data on baseline characteristics, psychosocial profiles, level of alcohol consumption before LT, disease course and treatment, and outcomes of LT. The interval of alcohol abstinence was defined as the time between last drink and the date of LT. The primary outcomes were survival and alcohol use after LT, defined as slip or sustained. Results: Among 147 patients with AH who received liver transplants, the median duration of abstinence before LT was 55 days; 54% received corticosteroids for AH and the patients had a median Lille score of 0.82 and a median Sodium Model for End-Stage Liver Disease score of 39. Cumulative patient survival percentages after LT were 94% at 1 year (95% confidence interval [CI], 89%-97%) and 84% at 3 years (95% CI, 75%-90%). Following hospital discharge after LT, 72% were abstinent, 18% had slips, and 11% had sustained alcohol use. The cumulative incidence of any alcohol use was 25% at 1 year (95% CI, 18%-34%) and 34% at 3 years (95% CI, 25%-44%) after LT. The cumulative incidence of sustained alcohol use was 10% at 1 year (95% CI, 6%-18%) and 17% at 3 years (95% CI, 10%-27%) after LT. In multivariable analysis, only younger age was associated with alcohol following LT (P = .01). Sustained alcohol use after LT was associated with increased risk of death (hazard ratio, 4.59; P = .01). Conclusions: In a retrospective analysis of 147 patients who underwent early LT (before 6 months of abstinence) for severe AH, we found that most patients survive for 1 year (94%) and 3 years (84%), similar to patients receiving liver transplants for other indications. Sustained alcohol use after LT was infrequent but associated with increased mortality. Our findings support the selective use of LT as a treatment for severe AH. Prospective studies are needed to optimize selection criteria, management of patients after LT, and long-term outcomes.

Impact of phosphatidylethanol in the surveillance for alcohol use in post‐liver transplant population: A retrospective study

Improved Detection of Alcohol Consumption Using the Novel Marker Phosphatidylethanol in the Transplant Setting: Results of A Prospective Study

Using phosphatidylethanol as an adjunct to self-reported alcohol use improves identification of liver fibrosis risk

Urinary Ethyl Glucuronide As a Novel Screening Tool in Patients Pre- and Post-Liver Transplantation Improves Detection of Alcohol Consumption.

The Survival Benefit of Re-abstinence After Harmful Alcohol Use Following Early Liver Transplant for Severe Alcohol-Associated Hepatitis: A Multi-Center ACCELERATE Study

You can't handle the truth! Comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patients

Utility of scores to predict alcohol use after liver transplant: Take them with a grain of salt

Characterization of the alcohol biomarker phosphatidylethanol in donor whole blood and apheresis red blood cells: Implications for transfusion recipients

Alcohol as a risk factor for mortality in liver transplant patients in Sweden

Phosphatidylethanol measures in patients with severe COVID‐19‐associated respiratory failure identify a subset with alcohol misuse

Safety of acamprosate for alcohol use disorder Post-Liver transplant: a pilot randomized controlled trial

S4378 Is Ignorance Bliss? The Use of PEth Studies in Alcohol-Associated Liver Disease

Management of Alcohol-Associated liver disease and alcohol use disorder in liver transplant candidates and recipients: Challenges and opportunities

Phosphatidylethanol as an outcome measure in treatment aimed at controlled drinking

Monitoring of the Alcohol Biomarkers Peth, Cdt and Etg/Ets in an Outpatient Treatment Setting

Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis

A false positive hair ethylglucuronide dosage in an alcohol abstinent patient after liver transplantation: a case report

Phosphatidylethanol Detects Occult Heavy Alcohol Use in Patients With Acute and Chronic Pancreatitis

Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis

Liver Transplantation in Alcohol-Associated Liver Disease: Current Status and Future Landscape

A Tailored Virtual Program for Alcohol Use Disorder Treatment Among Liver Transplant Candidates and Recipients Is Feasible and Associated With Lower Post-Transplant Relapse